Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

Journal of Medical Virology

Volumn 78, Issue 10, 2006, Pages 1276-1283

  Kobayashi, Mariko ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Kobayashi, Masahiro ^a   Iwasaki, Satomi ^a   Sato, Junko ^a   Watahiki, Sachiyo ^a   Miyakawa, Yuzo ^b   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Miyakawa Memorial Research Foundation   (Japan)

Author keywords

Chronic hepatitis; Cirrhosis; Genotypes; Hepatitis B virus; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LONG TERMINAL REPEAT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; VIRUS MUTANT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; FEMALE; GENETIC MARKERS; GENOME, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOSPITALS, URBAN; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TOKYO; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 33748638799     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20701     Document Type: Article

References (60)

1. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2003. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 38:315-321.
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
3. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. 2002. Genotype H: A new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 83:2059-2073.
4. Chan HL, Wong ML, Hui AY, Chim AM, Tse AM, Hung LC, Chan FK, Sung JJ. 2003. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 9:2695-2697.
5. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
6. Chien RN, Liaw YF, Atkins M. 1999. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30:770-774.
7. Chu CJ, Lok AS. 2002. Clinical significance of hepatitis B virus genotypes. Hepatology 35:1274-1276.
8. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
9. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology 124:105-117.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL. 2005. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352:2673-2681.
11. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 26:1393-1395.
12. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 365:123-129.
13. Kao JH, Chen PJ, Lai MY, Chen DS. 2000. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-559.
14. Kao JH, Liu CJ, Chen DS. 2002. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 36:303-304.
15. Kato H, Orito E, Sugauchi F, Ueda R, Gish RG, Usuda S, Miyakawa Y, Mizokami M. 2001. Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. J Virol Methods 98:153-159.
16. Kato H, Gish RG, Bzowej N, Newsom M, Sugauchi F, Tanaka Y, Kato T, Orito E, Usuda S, Ueda R, Miyakawa Y, Mizokami M. 2004. Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. J Med Virol 73:516-521.
17. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Takagi K, Miyakawa Y, Kumada H. 2002. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 68:522-528.
18. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Hosaka T, Someya T, Matsuda M, Sato J, Miyakawa Y, Kumada H. 2004. Wild-type precore and core promoter sequences in patients with acute self-limited or chronic hepatitis B. Scand J Gastroenterol 39:53-59.
19. Kobayashi M, Akuta N, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Hosaka T, Saitoh S, Kobayashi M, Someya T, Sato J, Watabiki S, Miyakawa Y, Kumada H. 2006. Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. J Med Virol 78:60-67.
20. Kumada H. 2003. Continued lamivudine therapy in patients with chronic hepatitis B. Intervirology 46:377-387.
21. Kuo A, Dienstag JL, Chung RT. 2004. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2:266-272.
22. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, Wu PC. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 25:241-244.
23. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
24. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. 1993. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: Possible contribution of a single nucleotide in the precore region. J Virol 67:5402-5410.
25. Liaw YF. 2002. Therapy of chronic hepatitis B: Current challenges and opportunities. J Viral Hepat 9:393-399.
26. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
27. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531.
28. Lindh M, Andersson AS, Gusdal A. 1997. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-Large-scale analysis using a new genotyping method. J Infect Dis 175:1285-1293.
29. Lok AS, McMahon BJ. 2001. Chronic hepatitis B. Hepatology 34:1225-1241.
30. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
31. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808-816.
32. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K. 2005. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 32:173-184.
33. Miyakawa Y, Mizokami M. 2003. Classifying hepatitis B virus genotypes. Intervirology 46:329-338.
34. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. 2005. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 12:398-404.
35. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC. 1997. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
36. Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO., 1992. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 73:1201-1208.
37. Ogawa M, Hasegawa K, Naritomi T, Torii N, Hayashi N. 2002. Clinical features and viral sequences of various genotypes of hepatitis B virus compared among patients with acute hepatitis B. Hepatol Res 23:167-177.
38. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M. 1988. Typing hepatitis B virus by homology in nucleotide sequence: Comparison of surface antigen subtypes. J Gen Virol 69:2575-2583.
39. Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M, Gojobori T. 1989. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci USA 86:7059-7062.
40. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. 2001. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33:218-223.
41. Rizzetto M. 2002. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 66:435-451.
42. Sherlock S. 1987. The natural history of hepatitis B. Postgrad Med J 63:S7-S11.
43. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. 2000. A new genotype of hepatitis B virus: Completegenome and phylogenetic relatedness. J Gen Virol 81:67-74.
44. Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J. 2005. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience. J Med Virol 75:391-398.
45. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K. 1999. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30:743-748.
46. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2002. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 37:922-927.
47. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Matsuda M, Satoh J, Takagi K, Kumada H. 2003a. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 46:182-189.
48. Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, Kobayashi M, Akuta N, Someya T, Miyakawa Y, Kumada H. 2003b. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 46:164-170.
49. Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, Hosaka T, Saitoh S, Kobayashi M, Someya T, Matsuda M, Sato J, Watabiki S, Miyakawa Y, Kumada H. 2005. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 76:33-39.
50. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. 1999. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
51. Thakur V, Sarin SK, Rehman S, Guptan RC, Kazim SN, Kumar S. 2005. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol 24:12-15.
52. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M. 1999. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 80:97-112.
53. Usuda S, Okamoto H, Tanaka T, Kidd-Ljunggren K, Holland PV, Miyakawa Y, Mayumi M. 2000. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. J Virol Methods 87:81-89.
54. Westland C, Delaney Wt, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. 2003. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 125:107-116.
55. Yotsuyanagi H, Okuse C, Yasuda K, Orito E, Nishiguchi S, Toyoda J, Tomita E, Hino K, Okita K, Murashima S, Sata M, Hoshino H, Miyakawa Y, Iino S. 2005. Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol 77:39-46.
56. Yuen MF, Tanaka Y, Lai CL. 2003a. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology 46:373-376.
57. Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. 2003b. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 8:531-534.
58. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 2001. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357:934-935.
59. Zollner B, Petersen J, Schafer P, Schroter M, Laufs R, Sterneck M, Feucht HH. 2002. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 34:1273-1277.
60. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH. 2004. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 39:42-50.